Multiparametric mri- and contrast enhanced ultrasound-targeted biopsy for the detection of significant prostate cancer: can we replace systematic biopsy?

Christophe Mannaerts (Corresponding author), Marc Engelbrecht, Arnoud Postema, Olivia Lodeizen, Rob van Kollenburg, Ruud van Sloun, Rogier Wildeboer, Massimo Mischi, Theo de Reijke, Hessel Wijkstra

Research output: Contribution to journalConference articleAcademicpeer-review

Abstract

Contrast-enhanced ultrasound (CEUS) with quantitative parametric imaging is currently not recommended for the detection of prostate cancer (PCa). Meanwhile, multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy (TBx) has evolved as an alternative to systematic transrectal ultrasound (TRUS)-guided biopsy (SBx). However, mpMRI before first biopsy remains controversial. In this prospective trial, we compared clinically significant (cs)PCa detection rates for MRI-TBx and CEUS-TBx with standard SBx in biopsy-naive men.
Original languageEnglish
Pages (from-to)e430-e430
Number of pages1
JournalJournal of Urology
Volume201
Issue number4S
DOIs
Publication statusPublished - 1 Apr 2019
Event114th American Urological Association Annual Meeting - Chicago, United States
Duration: 3 May 20196 May 2019
http://www.aua2019.org/

Fingerprint Dive into the research topics of 'Multiparametric mri- and contrast enhanced ultrasound-targeted biopsy for the detection of significant prostate cancer: can we replace systematic biopsy?'. Together they form a unique fingerprint.

  • Cite this